ReviewClinical microbiology reviews2016
Standardization of Assays That Detect Anti-Rubella Virus IgG Antibodies.
Review in Clinical microbiology reviews, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 61 citations in OpenAlex.
- Chronic inflammation in pregnant women with latent toxoplasmosis and explanation of discordant results of serological tests for toxoplasmosis.Folia parasitologica · 2025Article
- Seropositive Rubella and Toxoplasmosis Among Females Attending Saudi Hospital.Journal of tropical medicine · 2025Article
- Serosurveillance for Measles and Rubella.Vaccines · 2024Review
- A modified quality control protocol for infectious disease serology based on the Westgard rules.Scientific reports · 2024Article
- Seroprevalence and prevention of hepatitis B, measles and rubella among healthcare workers in Dili, Timor-Leste.The Lancet regional health. Southeast Asia · 2023Article
- Article
- Estimates of the basic reproduction number for rubella using seroprevalence data and indicator-based approaches.PLoS computational biology · 2022Article
- The Standardization and Control of Serology and Nucleic Acid Testing for Infectious Diseases.Clinical microbiology reviews · 2021Review
- Performance of the Abbott SARS-CoV-2 IgG II Quantitative Antibody Assay Including the New Variants of Concern, VOC 202012/V1 (United Kingdom) and VOC 202012/V2 (South Africa), and First Steps towards Global Harmonization of COVID-19 Antibody Methods.Journal of clinical microbiology · 2021Article
- Pitfalls of rubella serology while on the brink of elimination: evaluation of national data, Belgium, 2017.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2021Article
- Performance Characteristics of a Multiplex Flow Immunoassay for Detection of IgG-Class Antibodies to Measles, Mumps, Rubella, and Varicella-Zoster Viruses in Presumptively Immune Health Care Workers.Journal of clinical microbiology · 2020Article
- Performance of Zika Assays in the Context of Toxoplasma gondii, Parvovirus B19, Rubella Virus, and Cytomegalovirus (TORCH) Diagnostic Assays.Clinical microbiology reviews · 2019Review
- Rubella antibodies in Australian immunoglobulin products.Human vaccines & immunotherapeutics · 2017Article
- Characterization of rubella-specific humoral immunity following two doses of MMR vaccine using proteome microarray technology.PloS one · 2017Article
- Where to Now for Standardization of Anti-Rubella Virus IgG Testing.Journal of clinical microbiology · 2016Article
- Assessing Immunity to Rubella Virus: a Plea for Standardization of IgG (Immuno)assays.Journal of clinical microbiology · 2016Article
- Seroprevalence of Toxoplasmosis and rubella infection among women of childbearing age in Makkah Province, Saudi Arabia: a five-year, retrospective study.Annals of Saudi medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rubella virus usually causes a mild infection in humans but can cause congenital rubella syndrome (CRS). Vaccination programs have significantly decreased primary rubella virus infection and CRS; however, vaccinated individuals usually have lower levels of rubella virus IgG than those with natural infections. Rubella virus IgG is quantified with enzyme immunoassays that have been calibrated against the World Health Organization (WHO) international standard and report results in international units per milliliter. It is recognized that the results reported by these assays are not standardized. This investigation into the reasons for the lack of standardization found that the current WHO international standard (RUB-1-94) fails by three key metrological principles. The standard is not a pure analyte but is composed of pooled human immunoglobulin. It was not calibrated by certified reference methods; rather, superseded tests were used. Finally, no measurement uncertainty estimations have been provided. There is an analytical and clinical consequence to the lack of standardization of rubella virus IgG assays, which leads to misinterpretation of results. The current approach to standardization of rubella virus IgG assays has not achieved the desired results. A new approach is required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.